Platform & Therapeutics
Anticancer Therapeutic Strategy
"Through AI-powered BSP™ platform design, we are developing anticancer therapeutic recombinant proteins with structural characteristics distinct from conventional antibodies. Rather than directly overactivating immune cells, these proteins are designed to modulate structural and inflammatory signals within the tumor microenvironment (TME)."
01
Selectively binding to ECM / tumor ligands to precisely regulate the integrin–FAK–PI3K/AKT and NF-κB signaling axes
02
The ECM–integrin–FAK–NF-κB–EMT signaling axis serves as a common hub associated with metastasis, recurrence, and therapeutic resistance in various solid tumors, offering potential for broad pan-cancer expansion.
03
A clear tumor-suppressive effect (PoE) and distinct inhibition of mechanistic signals (FAK/PI3K/AKT, NF-κB) (PoM) were observed together, confirming the connection between mechanism and effect
1 Focus on cancer types with high unmet medical needs and secure an exclusive position during development
2 Design candidates around core mechanisms such as target blocking and signal inhibition
3 Operate a validation roadmap that optimizes efficacy and safety together in the preclinical stage
4 Strengthen partnering and expansion potential by accumulating data packages at each stage of development
Melanoma, pancreatic cancer (PDAC), ovarian cancer (HGSOC), triple-negative breast cancer (especially TNBC/EMT-high), hepatocellular carcinoma (HCC), lung cancer (CAF/ECM-high subset of NSCLC) Melanoma pancreatic cancer (PDAC) ovarian cancer (HGSOC) triple-negative breast cancer (especially TNBC/EMT-high) hepatocellular carcinoma (HCC) lung cancer (CAF/ECM-high subset of NSCLC)